Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced anticoagulation targets during ECMO
NL-OMON50046Phase 3Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of heparin and low molecular weight heparin calcium in heart failure (HF) and respiratory failure (3 arms), sponsored by University Medical Center Groningen. Primary endpoint: Composite primary endpoint. Started Oct 2020; status: recruiting.
02
Drugs
heparinlow molecular weight heparin calcium
03
Conditions
heart failure (HF)respiratory failure
Beyond the preview
Go deeper on NL-OMON50046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50046.